Stratatech Corporation’s StrataGraft® Skin Substitute Granted FDA Orphan Drug Designation  
6/13/2012 10:17:14 AM

MADISON, Wis.--(BUSINESS WIRE)--Stratatech Corp., a leader in regenerative medicine, today announced that StrataGraft®, the company’s universal human skin substitute, has been designated an orphan drug by the U.S. Food and Drug Administration for the treatment of partial and full thickness skin burns.